
I watched metabolic disease quietly take my grandparents and move through my family for thirty years. Then I became a transplant hepatologist and obesity medicine specialist to understand why. This is what I have learned.
| Platform | Pricing | Only free issues | Publishes | Weekly | |
|---|---|---|---|---|---|
| Issues | 29 | Founded | 2 years ago | Last Issue | 12 days ago |
| Active | |||||

When I see a new patient with metabolic liver disease, one of the first questions I ask is about their sleep.
Not their diet. Not their alcohol intake. Sleep.
The response is almost universal. They tell me their sleep is disrupted. When I...
In an analysis of pivotal cardiometabolic drug trials supporting FDA approval over a ten-year period, 81 percent of participants were White, 4 percent were Black, 12 percent were Asian, and 11 percent were Hispanic or Latino.
Read that ag...
For years, the prevailing assumption in hepatology was straightforward. Semaglutide and other GLP-1 medications improved liver disease primarily because patients lost weight. Less weight meant less visceral fat, reduced portal inflammatory...
There are microplastics in your liver right now.
That is not a hypothesis or an environmental warning about future risk. It is a measurable biological reality documented in peer-reviewed research. In postmortem human samples collected in 2...
Two patients came into my clinic recently, both Hispanic women in their sixties, both carrying significant metabolic liver disease. Each had brought her toddler grandchild to the appointment.
One of the grandchildren was holding a bottle o...
Subscribers, engagement, traffic and sponsorship for Inherited Risk.
| Subscribers | Engagement | 75 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
The writers behind this newsletter.
I watched metabolic disease quietly take my grandparents and move through my family for thirty years. Then I became a transplant hepatologist and obesity medicine specialist to understand why. This is what I have learned. Views are my own.
Author of bestselling book "The Psychobiotic Revolution" from National Geographic with the brilliant Ted Dinan and John Cryan. Get the latest on the hot field of gut-brain research, with info on how you can benefit.
Preventive and performance cardiologist writing about physiologic reserve: the capacity you build now that determines how you age. Evidence-based, through the eyes of a practicing clinician.
You can find recent issues that have been published by Inherited Risk on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to Inherited Risk, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch Inherited Risk as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Inherited Risk using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like Inherited Risk. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.